Entities / Company
Rhythm (United states).
company in Boston, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Rhythm develops precision medicines for rare genetic diseases, benefiting from tariffs and attracting analyst buy ratings.Some support2 reports
-
An offering was managed by Morgan Stanley, BofA Securities, Citigroup, and BNP Paribas, with the registration statement filed and declared effective by the SEC (Bangladesh) on September 5, 2025.Some support7 reports
-
Rhythm company received FDA approval for its lead asset, IMCIVREE, following a fireside chat in Boston.Some support2 reports
-
Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.Some support1 report
-
Rhythm presented clinical data at the Endocrine Society’s Annual Meeting in July 2025.Some support1 report
-
Zacks model analyzed estimate revisions for earnings for Rhythm on July 29, 2025.Some support1 report
-
Rhythm, a company in the biomedical and genetics industry, outperformed the S&P 500 market index.Some support2 reports
-
FDA accepted Rhythm's supplemental New Drug Application, and Morgan Stanley reiterated a Buy rating, while the European Medicines Agency is reviewing the drug.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Rhythm (United states) this week
News at the entities that move Rhythm (United states) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Rhythm (United states)
-
UWM Holdings Corp filed an 8-K with the Securities and Exchange Commission (Bangladesh) on May 13, 2026.
Moves Rhythm (United states)
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Rhythm (United states)
-
Europe OperationalThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Rhythm (United states)
-
Boston Shared contextThe Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Moves Rhythm (United states)
Connections
The 5 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates Rhythm's pharmaceutical products, including reviewing and approving new drug applications.
-
Rhythm is subject to formal regulation by the Securities and Exchange Commission of Bangladesh.
-
Morgan Stanley Transactional
Morgan Stanley served as a joint book-running manager and provided a Buy rating for Rhythm.
-
Europe Operational
Rhythm is actively pursuing label expansion and drug review processes within the European market.
-
Boston Shared context
Rhythm Pharmaceuticals is headquartered and operates within the city of Boston.
History
Events by the month they beganJune 2026
8 events- Rhythm develops precision medicines for rare genetic diseases, benefiting from tariffs and attracting analyst buy ratings.
- An offering was managed by Morgan Stanley, BofA Securities, Citigroup, and BNP Paribas, with the registration statement filed and declared effective by the SEC (Bangladesh) on September 5, 2025.
- Rhythm company received FDA approval for its lead asset, IMCIVREE, following a fireside chat in Boston.
- Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.
- Rhythm presented clinical data at the Endocrine Society’s Annual Meeting in July 2025.
- Zacks model analyzed estimate revisions for earnings for Rhythm on July 29, 2025.
- Rhythm, a company in the biomedical and genetics industry, outperformed the S&P 500 market index.
- FDA accepted Rhythm's supplemental New Drug Application, and Morgan Stanley reiterated a Buy rating, while the European Medicines Agency is reviewing the drug.